Plant Name: Abutilon indicum
Taxonomic Information:
Plant ID: NPO24749
Plant Latin Name: Abutilon indicum
Taxonomy Genus: Abutilon
Taxonomy Family: Malvaceae
Plant External Links:
NCBI TaxonomyDB:
318060
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Philippines; Indonesia; India; Malaysia; China; ThailandTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCMGeographical Distribution:
Philippines; Indonesia; India; Malaysia; China; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| AR; NR3C2; PGR; NR3C1; | |
| NR1H4; | |
| NR1I2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Nuclear hormone receptor subfamily 3 group C | NR3C2 | Mineralocorticoid receptor | P08235 | CHEMBL1994 |
| Nuclear hormone receptor subfamily 3 group C | PGR | Progesterone receptor | P06401 | CHEMBL208 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.940E-13 | 2.078E-09 | AR, NR1H4, NR1I2, NR3C1, NR3C2, PGR |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 9.297E-12 | 3.374E-08 | AR, NR1H4, NR3C1, NR3C2, PGR |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 5.460E-10 | 1.321E-06 | AR, NR1H4, NR1I2, PGR |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.462E-09 | 1.189E-05 | AR, NR1H4, NR1I2, NR3C1, NR3C2, PGR |
| MF | GO:0005488; binding | GO:0000977; RNA polymerase II regulatory region sequence-specific DNA binding | 2.105E-07 | 2.696E-04 | AR, NR1H4, NR1I2, NR3C1, PGR |
| BP | GO:0022414; reproductive process | GO:0060748; tertiary branching involved in mammary gland duct morphogenesis | 2.412E-07 | 2.918E-04 | AR, PGR |
| MF | Unclassified; | GO:0004872; receptor activity | 2.698E-07 | 3.092E-04 | AR, NR1H4, NR1I2, NR3C1, NR3C2, PGR |
| MF | GO:0140110; transcription regulator activity | GO:0001077; transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding | 5.727E-07 | 4.618E-04 | AR, NR1H4, NR3C1, PGR |
| BP | GO:0009987; cellular process | GO:0030518; intracellular steroid hormone receptor signaling pathway | 1.256E-06 | 8.821E-04 | AR, NR3C1, PGR |
| BP | GO:0008152; metabolic process | GO:0045944; positive regulation of transcription from RNA polymerase II promoter | 3.395E-06 | 2.240E-03 | AR, NR1H4, NR1I2, NR3C1, PGR |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 6.251E-16 | 1.361E-11 | AR, NR1H4, NR1I2, NR3C1, NR3C2, PGR |
| CC | GO:0043226; organelle | GO:0016607; nuclear speck | 5.189E-03 | 4.955E-01 | AR, NR3C1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 5.537E-04 | 3.876E-03 | AR, PGR |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 1.164E-02 | 4.066E-02 | NR3C2 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.641E-02 | 4.066E-02 | AR |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.111E-02 | 4.066E-02 | NR1H4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.905E-02 | 4.066E-02 | PGR |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 8.028E-02 | 9.367E-02 | NR3C1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.134E-01 | 1.134E-01 | AR |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | PGR; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; PGR; |
| NA: NA | Male hypogonadism | NA | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR; |
| N00-N99: Diseases of the genitourinary system | Menstrual disorders | N91-N95 | PGR; |
| N00-N99: Diseases of the genitourinary system | Gynecological disorder | N70-N98 | PGR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; PGR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; |
| C00-D49: Neoplasms | Uterine leiomyoma | D25 | PGR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; |
| C00-D49: Neoplasms | Uterine fibroids | D25 | PGR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR; |
| Z00-Z99: Factors influencing health status and contact with health services | Female contraception | Z30 | PGR; |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | PGR; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormonal contraceptives | Z30 | PGR; |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR; |
| C00-D49: Neoplasms | Advanced endometrium carcinoma | NA | PGR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; |
| C00-D49: Neoplasms | Advanced breast carcinoma | NA | PGR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; PGR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PGR; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PGR; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
